Leap Therapeutics, Inc. (NASDAQ: LPTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced the initiation of Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap’s anti-SSEDickkopf 1 (DKK1) antibody, in combination with tislelizumab, BeiGene’s anti-PD-1 antibody.
July 12, 2022
· 10 min read